Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ajpath.2015.11.003 http://scihub22266oqcxt.onion/10.1016/j.ajpath.2015.11.003 C4816696!4816696 !26801735     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26801735 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Pathol 2016 ; 186 (3 ): 678-90 Nephropedia Template TP {{tp|p=26801735 |t=2016. Inhibition of Transforming Growth Factor-? Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma |pdf=|usr=}}{{26801735 }} gab.com Text Inhibition of Transforming Growth Factor- Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma JO: Am J Pathol http://www.kidney.de/pget.php?&tw=1&pmid=26801735 #FOAvip Transforming growth factor (TGF)-? supports multiple myeloma progression and associated osteolytic bone disease. Conversion of latent TGF-? to its biologically active form is a major regulatory node controlling its activity. Thrombospondin1 (TSP1) binds and activates TGF-?. TSP1 is increased in myeloma, and TSP1-TGF-? activation inhibits osteoblast differentiation. We hypothesized that TSP1 regulates TGF-? activity in myeloma and that antagonism of the TSP1-TGF-? axis inhibits myeloma progression. Antagonists (LSKL peptide, SRI31277) derived from the LSKL sequence of latent TGF-? that block TSP1-TGF-? activation were used to determine the role of the TSP1-TGF-? pathway in mouse models of myeloma. TSP1 binds to human myeloma cells and activates TGF-? produced by cultured human and mouse myeloma cell lines. Antagonists delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of aggressive myeloma reduced TGF-? signaling (phospho-Smad 2) in bone sections, tumor burden, mouse IL-6, and osteoclasts, increased osteoblast number, and inhibited bone destruction as measured by microcomputed tomography. SRI31277 reduced tumor burden in the immune competent 5TGM1 myeloma model. SRI31277 was as effective as dexamethasone or bortezomib, and SRI31277 combined with bortezomib showed greater tumor reduction than either agent alone. These studies validate TSP1-regulated TGF-? activation as a therapeutic strategy for targeted inhibition of TGF-? in myeloma. Twit Text FOAVip Inhibition of Transforming Growth Factor- Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma ????Am J Pathol http://www.kidney.de/pget.php?&tw=1&pmid=26801735 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26801735 #FOAvip English Wikipedia <ref>{{Cite pmid|26801735 }}</ref> Inhibition of Transforming Growth Factor-? Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma #MMPMID26801735 Lu A ; Pallero MA ; Lei W ; Hong H ; Yang Y ; Suto MJ ; Murphy-Ullrich JE Am J Pathol 2016[Mar]; 186 (3 ): 678-90 PMID26801735 show ga Transforming growth factor (TGF)-? supports multiple myeloma progression and associated osteolytic bone disease. Conversion of latent TGF-? to its biologically active form is a major regulatory node controlling its activity. Thrombospondin1 (TSP1) binds and activates TGF-?. TSP1 is increased in myeloma, and TSP1-TGF-? activation inhibits osteoblast differentiation. We hypothesized that TSP1 regulates TGF-? activity in myeloma and that antagonism of the TSP1-TGF-? axis inhibits myeloma progression. Antagonists (LSKL peptide, SRI31277) derived from the LSKL sequence of latent TGF-? that block TSP1-TGF-? activation were used to determine the role of the TSP1-TGF-? pathway in mouse models of myeloma. TSP1 binds to human myeloma cells and activates TGF-? produced by cultured human and mouse myeloma cell lines. Antagonists delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of aggressive myeloma reduced TGF-? signaling (phospho-Smad 2) in bone sections, tumor burden, mouse IL-6, and osteoclasts, increased osteoblast number, and inhibited bone destruction as measured by microcomputed tomography. SRI31277 reduced tumor burden in the immune competent 5TGM1 myeloma model. SRI31277 was as effective as dexamethasone or bortezomib, and SRI31277 combined with bortezomib showed greater tumor reduction than either agent alone. These studies validate TSP1-regulated TGF-? activation as a therapeutic strategy for targeted inhibition of TGF-? in myeloma. |Animals [MESH] |Antineoplastic Agents/therapeutic use [MESH] |Bortezomib/therapeutic use [MESH] |Cell Differentiation/drug effects [MESH] |Disease Models, Animal [MESH] |Humans [MESH] |Interleukin-6/metabolism [MESH] |Male [MESH] |Mice [MESH] |Mice, Inbred C57BL [MESH] |Mice, SCID [MESH] |Multiple Myeloma/*drug therapy/pathology [MESH] |Osteogenesis/drug effects [MESH] |Osteolysis/*drug therapy/pathology [MESH] |Peptides/*pharmacology/therapeutic use [MESH] |Random Allocation [MESH] |Signal Transduction/drug effects [MESH] |Thrombospondin 1/*drug effects/metabolism [MESH] |Transforming Growth Factor beta/*antagonists & inhibitors/metabolism [MESH]Inhibition of Transforming Growth Factor-? Activation Diminishes Tumor(epmc).pdf DeepDyve Pubget Overpricing